Jefferies Group LLC Lineage Cell Therapeutics, Inc. Transaction History
Jefferies Group LLC
- $10.2 Billion
- Q3 2022
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$21.2 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.88 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$4.4 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$3.69 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$3.04 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $86.6M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...